Inhibition of angiotensin-converting enzyme reduces susceptibility of hypertrophied rat myocardium to ventricular fibrillation

Circulation Journal

Volumn 66, Issue 11, 2002, Pages 1045-1053

  Shimada, Yasuyuki ^b   Gunasegaram, Suba ^a   Yokoyama, Hiroyuki ^a   Avkiran, Metin ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Atrial natriuretic factor; Hypertrophy; Ischemia induced arrhythmias

Indexed keywords

ATRIAL NATRIURETIC FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MESSENGER RNA; RAMIPRIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME INHIBITION; HEART ARRHYTHMIA; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE HYPERTROPHY; MALE; NONHUMAN; RAT; ANIMAL; CARDIOMEGALY; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; GENETICS; HEART MUSCLE CELL; HEART VENTRICLE; PATHOLOGY; REPERFUSION INJURY; WISTAR RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ATRIAL NATRIURETIC FACTOR; CARDIOMEGALY; DISEASE MODELS, ANIMAL; HEART VENTRICLES; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; RAMIPRIL; RATS; RATS, WISTAR; RNA, MESSENGER; VENTRICULAR FIBRILLATION;

EID: 0036859602     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.66.1045     Document Type: Article

References (62)

1. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: The Framingham heart study. Am J Cardiol 1987; 60: 560-565.
2. Aronow WS, Epstein S, Koenisberg M, Schwartz KS. Usefulness of echocardiographic left ventricular hypertrophy, ventricular tachycardia and complex ventricular arrhythmias in predicting ventricular fibrillation or sudden cardiac death in elderly patients. Am J Cardiol 1988; 62: 1124-1125.
3. Dunn FG, Pringle SD. Sudden cardiac death, ventricular arrhythmias and hypertensive left ventricular hypertrophy. J Hypertens 1993; 11: 1003-1010.
4. Burke AP, Farb A. Sessums L, Virmani R. Causes of sudden cardiac death in patients with replacement valves: An autopsy study. J Heart Valve Dis 1994; 3: 10-16.
5. Thakur RK. Ventricular arrhythmias in the elderly. Can J Cardiol 1994; 10: 119-124.
6. James BM, William K, Melvin LM. Chronic hypertension and left ventricular hypertrophy facilitate induction of sustained ventricular tachycardia in dogs 3 hours after left circumflex coronary artery occlusion. J Am Coll Cardiol 1989; 14: 1365-1373.
7. Shimada Y, Hearse DJ, Avkiran M. Ischaemia- and reperfusion-induced arrhythmias in LV hypertrophy. J Mol Cell Cardiol 1994; 26: CVII.
8. Yokoshiki H, Kohya T, Tohse N, Kanno M, Nakaya H, Saito H, et al. Regression of left ventricular hypertrophy prevents sudden cardiac death by ischemia induced lethal arrhythmias-beneficial effect of angiotensin II blockade. Circ Res 1995; 76: 892-899.
9. 31P nuclear magnetic resonance studies of ischemia-induced ventricular fibrillation: Alterations of intracellular Na and cellular energy. Circ Res 1995; 77: 394-406.
10. Robertson E, Hof RP, Ziehut W. Effect of hypertrophy induced by pressure overload or volume overload on reperfusion induced arrhythmias in anesthetised rats. Cardiovasc Res 1993; 27: 515519.
11. Taylor AL, Winter R, Thandroyen F, Murphree S, Buja LM, Eckels R, et al. Potentiation of reperfusion-associated ventricular fibrillation by left ventricular hypertrophy. Circ Res 1990; 67: 501-509.
12. Anversa P, Loud AV, Giacomelli F, Wiener J. Absolute morphometric study of myocardial hypertrophy in experimental hypertension. II: Ultrastructure of myocytes and interstitium. Lab Invest 1978; 38: 597-608.
13. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865.
14. Pye MP, Cobbe SM. Mechanisms of ventricular arrhythmias in cardiac failure and hypertrophy. Cardiovasc Res 1992; 26: 740-750.
15. Pahor M, Bernabei R, Sgadari A, Gambassi G Jr, Lo Giudice P, Pacifici L, et al. Enalapril prevents cardiac fibrosis and arrhythmias in hypertensive rats. Hypertension 1991; 18: 148-157.
16. Nguyen T, Salibi EE, Rouleau JL. Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneous hypertensive rat: Effects of ramipril and hydralazine. Circulation 1998; 98: 2074-2080.
17. Linz W, Wiemer G, Schaper J, Zimmermann R, Nagasawa K, Gohlke P, et al. Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis. Mol Cell Biochem 1995; 147: 89-97.
18. Kawabata H, Ryomoto T, Ishikawa K. Effect of angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor antagonist on metabolism and contraction in ischemia-reperfused rabbit heart. Jpn Circ J 2000; 64: 276-282.
19. Baxter GF, Yellon DM. Regression of left ventricular hypertrophy and susceptibility to reperfusion-induced arrhythmias after DOCA-salt hypertension in the rat. Cardioscience 1992; 3: 245-250.
20. Levy LB, Avkiran M, Ferrari R, Hearse DJ. Impaired skeletal muscle fatigue resistance in rats with pressure overloaded-induced left ventricular hypertrophy. J Mol Cell Cardiol 1996; 28: 183-195.
21. Avkiran M, Curtis MJ. Independent dual perfusion of left and right coronary arteries in isolated rat hearts. Am J Physiol 1991; 261: H2082-H2090.
22. Bishop JE, Laurent GJ. Collagen turnover and its regulation in the normal and hypertrophying heart. Eur Heart J 1995; 16(Suppl C): 38-44.
23. Milano CA, Dolber PC, Rockman HA, Bond RA, Venable ME, Allen LF, et al. Myocardial expression of a constitutively active α1b-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Nat Acad Sci 1994; 91: 10109-10113.
24. Kaiser M, Kahr O, Shimada Y, Smith P, Kelly M, Mahadeva H, et al. Differential regulation of ventricular adrenomedullin and atrial natriuretic peptide gene expression. Clin Sci 1998; 94: 359-365.
25. Walker MJ, Curtis MJ, Hearse DJ, Campbell RW, Janse MJ. Yellon DM, et al. The Lambeth Conventions: Guidelines for the study of arrhythmias in ischemia, infarction, and reperfusion. Cardiovasc Res 1988; 22: 447-455.
26. Maxwell MP, Hearse DJ, Yellon DM. Species variation in the coronary collateral circulation during regional myocardial ischemia: A critical determinant of the rat of evolution and extent of myocardial infarction. Cardiovasc Res 1987; 21: 737-746.
27. Dakkak R, Dreux C. Automatisation du dosage de I'hydroxyprolinurie après isolement et hydrolyse des hydropeptides sur résine échangeuse d'ions. Ann Biol Clin 1976; 34: 197-202.
28. Tytgat J. How to isolate cardiac myocytes. Cardiovasc Res 1994; 28: 280-283.
29. Mitra R, Morad M. A uniform enzymatic method for dissociation of myocytes from hearts and stomachs of vertebrates. Am J Physiol 1985; 249: H1056-H1060.
30. + exchanger during postnatal development in the rat: Changes in mRNA expression and sarcolemmal activity. J Mol Cell Cardiol 1997; 29: 321-332.
31. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res 1980; 47: 1-9.
32. Shimada Y, Avkiran M. Attenuation of reperfusion arrhythmias by selective inhibition of ACE/kininase II in the ischemic zone: Mediated by endogenous bradykinin? J Cardiovasc Pharmacol 1996; 27: 428-438.
33. Linz W, Schölkens BA. Role of bradykinin in the cardiac effects of angiotensin converting enzyme inhibitors. J Cardiovasc Pharmacol 1992; 20(Suppl 9): s83-s90.
34. Linz W, Rainer H, Schölkens BA. Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats. J Hypertens 1991; 9(Suppl 6): S400-S401.
35. Linz W, Schaper J, Wiemer G, Albus U, Schölkens BA. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: A one year study in rats. Br J Pharmacol 1992; 107: 970-975.
36. Unger T, Mattfeldt T, Bock P, Lamberty V, Mall G, Linz W, et al. Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries. Hypertension 1992; 20: 478-482.
37. Mohabir R, Young SD, Strosberg AM. Role of angiotensin in pressure overload induced hypertrophy in rats: Effects of angiotensin converting enzyme inhibitors, an AT1 receptor antagonist, and surgical reversal. J Cardiovasc Pharmacol 1994; 23: 291-299.
38. Zierhut Wp, Zimmer HG, Gerdes AM. Effect of angiotensin converting enzyme inhibition on pressure-induced left ventricular hypertrophy in rats. Circ Res 1991; 69: 609-617.
39. Weinberg EO, Schoen FJ, George D, Kagaya Y, Douglas PS, Litwin SE, et al. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 1994; 90: 1410-1422.
40. Linz W, Schölkens BA. A specific B2 bradykinin receptor antagonist HOE140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992; 105: 771-772.
41. Linz W, Wiemer G, Schölkens BA. Contribution of bradykinin to the cardiovascular effects of ramipril. J Cardiovasc Pharmacol 1993; 22(Suppl 9): S1-S8.
42. Gohlke P, Linz W, Schölkens BA, Kuwer I, Bartenbach S, Schnell A, et al. Angiotensin-converting enzyme inhibition improves cardiac function: Role of bradykinin. Hypertension 1994; 23: 411-418.
43. Pahor M, Gambassi G, Carbonin P. Antiarrhythmic effects of ACE inhibitors: A matter of faith or reality? Cardiovasc Res 1994; 28: 173-182.
44. Nadal Ginard B, Mahdavi V. Molecular basis of cardiac performance: Plasticity of the myocardium generated through protein isoform switches. J Clin Invest 1989; 84: 1693-1700.
45. Parker TG, Schneider MD. Growth factors, proto-oncogenes, and plasticity of the cardiac phenotype. Annu Rev Physiol 1991; 53: 179-200.
46. Simpson PC, Long CS, Waspe LE, Henrich CJ, Ordahl CP. Transcription of early developmental isogenes in cardiac myocyte hypertrophy. J Mol Cell Cardiol 1989; 21(Suppl V): 79-89.
47. Michel JB, Lattion AL, Salzmann JL, Cerol ML, Philippe M, Camilleri JP, et al. Hormonal and cardiac effects of converting enzyme inhibition in rat myocardial infarction. Circ Res 1988; 62: 641-650.
48. Wollert KC, Studer R, von Bulow B, Drexler H. Survival after myocardial infarction in the rat: Role of tissue angiotensin-converting enzyme inhibition. Circulation 1994; 90: 2457-2467.
49. Long CS, Kariya K, Karns L, Simpson PC. Sympathetic modulation of the cardiac myocyte phenotype: Studies with a cell-culture model of myocardial hypertrophy. Basic Res Cardiol 1992; 87(Suppl 2): 19-31.
50. Kariya K, Karns LR, Simpson PC. An enhancer core element mediates stimulation of the rat beta-myosin heavy chain promoter by an alpha 1-adrenergic agonist and activated beta-protein kinase C in hypertrophy of cardiac myocytes. J Biol Chem 1994; 269: 3775-3782.
51. + exchange and reperfusion arrhythmias: Protection by intracoronary infusion of a novel inhibitor. Am J Physiol 1994; 267: H2430-H2440.
52. Yasutake M, Avkiran M. Exacerbation of reperfusion arrhythmias by al Adrenergic stimulation: A potential role for receptor mediated activation of sarcolemmal sodium-hydrogen exchange. Cardiovasc Res 1995; 29: 222-230.
53. Pringle SD, Dunn FG, Macfarlane PW, McKillop JH, Lorimer AR, Cobbe SM. Significance of ventricular arrhythmias in systemic hypertension with left ventricular hypertrophy. Am J Cardiol 1992; 69: 913-917.
54. Richard AM, Nicholls MG, Crozier IG. Role of ACE inhibitors in hypertension with left ventricular hypertrophy. Br Heart J 1994; 72: S24-S32.
55. Michel JB. Relationship between decrease in afterload and beneficial effects of ACE inhibitors in experimental cardiac hypertrophy and congestive heart failure. Eur Heart J 1990; 11(Suppl D): 17-26.
56. Webster MWI, Fitzpatrick MA, Nicholls MG, Ikram H, Wells JE. Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol 1985; 56: 566-569.
57. Takezako T, Zhang B, Serikawa T, Fan P, Nomoto J, Saku K. The D allele of the angiotensin-converting enzyme gene and reperfusioninduced ventricular arrhythmias in patients with acute myocardial infarction. Jpn Circ J 2001; 65: 603-609.
58. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
59. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-691.
60. Shimada Y, Hearse DJ, Avkiran M. Left and right coronary reserve in LV hypertrophy: Effects of ACE inhibition. J Mol Cell Cardiol 1995; 27: A369.
61. Yamamoto H, Avkiran M. Left ventricular pressure overload during postnatal development: Effects on coronary vasodilator reserve and tolerance to hypothermic global ischemia. J Thorac Cardiovasc Surg 1993; 105: 120-131.
62. Ibuki C, Hearse DJ, Avkiran M. Rate of reflow and reperfusion induced arrhythmias: Studies with dual coronary perfusion. Cardiovasc Res 1992; 26: 316-323.